Blue Cross Blue Shield · Bylvay · US health-plan appeal rights

Bylvay denied for failing step therapy by Blue Cross Blue Shield?

Q: How long do I have to appeal a Blue Cross Blue Shield Bylvay denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Step-therapy denials usually flip when the appeal documents that prior alternatives were tried and failed, or were contraindicated, or aren't safe for the patient.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-10

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Blue Cross Blue Shield typically requires

Blue Cross Blue Shield's specific coverage criteria for bylvay are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: BCBS Specialty Pharmacy — IBAT inhibitors (Bylvay, Livmarli) for PFIC / Alagille

The Blue Cross Blue Shield angle on Bylvay

## Why BCBS Denied Bylvay Under Step Therapy

Blue Cross Blue Shield's step-therapy (also called "fail-first") protocol for Bylvay (odevixibat) requires that the patient try one or more less-expensive agents that BCBS considers clinically comparable before it will approve coverage of Bylvay. For rare cholestatic liver diseases, this presents a specific challenge: there may be very few or no true therapeutic equivalents for the underlying condition, and requiring a trial of an unrelated or less-effective agent can cause meaningful clinical harm. Most states now have step-therapy override laws, and federal protections provide additional pathways.

## Why It Is Appealable

Step-therapy denials must satisfy a "clinically appropriate" standard. If BCBS's required first-step drugs are not approved for or clinically appropriate in your specific diagnosis, the step-therapy requirement cannot lawfully be applied. In addition, if you have already tried and failed the required step(s), that history satisfies the protocol. Your federal rights:

ACA §2719 / ERISA §503: Full internal appeal plus independent external review.
External review window: Typically four months from the final internal denial — confirm on your Explanation of Benefits.
State step-therapy override laws: Many states require insurers to grant a step-therapy exception when (a) the required drug is contraindicated or clinically inappropriate, (b) the patient already failed the required step, or (c) the required drug would cause adverse clinical outcomes. Confirm your state's law applies to your plan type.
Expedited review: Available when delay poses urgent clinical risk.

## Appeal Process and Timeline

1. Request the denial in writing identifying the specific drug(s) BCBS requires as a first step. 2. Assess each required step drug: Did the patient try it? Did it fail, cause an adverse event, or is it clinically inappropriate for the specific diagnosis? Document each answer. 3. File a step-therapy exception/internal appeal with supporting documentation. 4. Escalate to external review if the internal appeal is denied.

## Documentation to Gather

Prior therapy history: A dated record of every step-therapy drug tried, the duration, and the documented outcome (failure, adverse event, intolerance, or clinical contraindication).
Clinical inappropriateness rationale: If a required step drug has not been tried because it is not indicated for your specific diagnosis subtype, your prescriber should document this explicitly, citing the FDA label of the step drug and the relevant specialty-society guideline organization.
Diagnosis confirmation: Specialist chart notes, genetic testing, and lab findings confirming the specific condition and its severity.
Prescriber exception letter: Requesting the step-therapy override and addressing each of the override criteria in your state's law and BCBS's published policy.
Bylvay medical-necessity documentation: Even with a step-therapy exception, BCBS will require evidence that Bylvay itself meets medical-necessity criteria — include the full documentation set described under the medical-necessity denial type.

## Criteria-Mapping Structure

Obtain BCBS's step-therapy policy and the FDA labels for each required step drug. For each required step: (1) state whether it was tried (with dates and outcomes), or (2) explain why it is clinically inappropriate for this patient's specific diagnosis. Then map Bylvay's FDA criteria to the chart facts. A structured, criterion-by-criterion response is the most effective format for step-therapy appeals.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Blue Cross Blue Shield appeals

Other denial reasons for Blue Cross Blue Shield Bylvay

denied as not medically necessary denied as non-formulary denied for missing prior authorization denied as experimental or investigational denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-10. Editorial standards: denialhelp.com/authors.